BARCELONA (Reuters) - Johnson & Johnson's JNJ.N Janssen unit will begin mid-stage trials of its COVID-19 vaccine in Spain on Monday, the programme's lead investigator said.
Alberto Borobia said 190 people would take part in the country’s trials, which will take place in three hospitals and be concluded by Sept. 22.
The Spanish study is part of mid-stage, or Phase II, trials of the vaccine that are being carried out in three countries, also including the Netherlands and Germany. The trials in the three countries will last two months and include 550 participants in total.
Reporting by Graham Keeley; Editing by Pravin Char
Our Standards: The Thomson Reuters Trust Principles.